Pancreatic Cancer Research

ResearcherNagoya University HospitalActive in the last 2 years

Takuya Ishikawa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5814-3555; OpenAlex author ID A5090551412, A5128893032, A5152870495. Sources: OpenAlex.

Their work

Papers
27 (first author 7, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
49
Papers, trials and grants by year

2018: 2 papers · 2019: 2 papers · 2020: 2 papers · 2021: 2 papers · 2022: 8 papers · 2023: 2 papers · 2024: 1 paper · 2025: 1 paper · 2026: 7 papers

Papers 27

  1. Neoadjuvant Chemotherapy (FOLFIRINOX or Gemcitabine With Nab-Paclitaxel) for Borderline-Resectable Pancreatic Cancer: Long-Term Results of a Randomized Control… Co-author DOI 10.1002/jhbp.70150↗
  2. Pretreatment Contrast-Enhanced Harmonic EUS Predicts Pathological Response and Recurrence-Free Survival After Multimodal Treatment in Resectable Pancreatic Can… First author DOI 10.1002/jhbp.70180↗
  3. Response to the letter to the editor regarding "Concealed pancreatic cancer in acute pancreatitis: Early MRCP and EUS surveillance improves prognosis and ident… Co-author DOI 10.1016/j.pan.2025.12.005↗
  4. Endoscopic ultrasound-guided fiducial marker placement for image-guided proton beam therapy in pancreatic cancer: implications for positional accuracy and posi… First author DOI 10.1093/jrr/rrag082↗
  5. FOLFIRINOX vs. Gemcitabine/Nab-Paclitaxel for Pancreatic Cancer by BRCA2 and TMB Status: A Japanese C-CAT Database Study. First author DOI 10.1111/cas.70351↗
  6. Operator-rated puncture performance and first-pass lesion tissue area in pancreatic ductal adenocarcinoma: an exploratory single-center sub-analysis of endosco… First author DOI 10.21203/rs.3.rs-11273454/v1↗
  7. Utility of endoscopic ultrasonography elastography as a predictive tool for post-treatment recurrence of resectable pancreatic cancer treated with neoadjuvant … First author DOI 10.5946/ce.2025.414↗
  8. Concealed pancreatic cancer in acute pancreatitis: Early MRCP and EUS surveillance improves prognosis and identifies high-risk patients. Co-author DOI 10.1016/j.pan.2025.02.013↗
  9. Impact of sarcopenia on biliary drainage during neoadjuvant therapy for pancreatic cancer. Co-author DOI 10.5946/ce.2022.278↗
  10. Usefulness of Endoscopic Ultrasound Elastography and Contrast-Enhanced Endoscopic Ultrasound in the Diagnosis of Pancreatic Cancer of 10 mm or Less Co-author DOI 10.21203/rs.3.rs-3014153/v1↗
  11. Current Status of the Diagnosis of Early-Stage Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/diagnostics13020215↗
  12. Comparison of contrast-enhanced transabdominal ultrasonography following endoscopic ultrasonography with GD-EOB-DTPA-enhanced MRI for the sequential diagnosis … Co-author DOI 10.1002/jhbp.1097↗
  13. Comparison of outcomes between secondary fully covered and uncovered self-expandable metal stents in the treatment of recurrent biliary obstruction of pancreat… Co-author DOI 10.1007/s00464-021-08981-2↗
  14. Selection of chemotherapy for older patients with pancreatic cancer based on geriatric assessment. Co-author DOI 10.1016/j.jgo.2022.09.005↗
  15. Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves the sensitivity of pancreatic cancer to … Co-author DOI 10.1038/s41388-022-02288-9↗
  16. Correction: Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves the sensitivity of pancreati… Co-author DOI 10.1038/s41388-022-02336-4↗
  17. Author Correction: Variability measurements provide additional value to shear wave elastography in the diagnosis of pancreatic cancer. First author DOI 10.1038/s41598-022-21219-y↗
  18. Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM/nab-PTX) for Borderline-resectable Pancreatic Cancer (NUPAT-01). Co-author DOI 10.1097/sla.0000000000005430↗
  19. Safety and efficacy of MIKE-1 in patients with advanced pancreatic cancer: a study protocol for an open-label phase I/II investigator-initiated clinical trial … Co-author DOI 10.1186/s12885-022-09272-2↗
  20. Utility of multiphase contrast enhancement patterns on CEH-EUS for the differential diagnosis of IPMN-derived and conventional pancreatic cancer. Co-author DOI 10.1016/j.pan.2020.12.022↗
  21. Variability measurements provide additional value to shear wave elastography in the diagnosis of pancreatic cancer. First author DOI 10.1038/s41598-021-86979-5↗
  22. Risks and characteristics of pancreatic cancer and pancreatic relapse in autoimmune pancreatitis patients. Co-author DOI 10.1111/jgh.15163↗
  23. Diagnosis of vascular invasion in pancreatic ductal adenocarcinoma using endoscopic ultrasound elastography. Co-author DOI 10.1186/s12876-020-01228-9↗
  24. Randomized Phase II Study of Consecutive-Day versus Alternate-Day Treatment with S-1 as Second-Line Chemotherapy in Advanced Pancreatic Cancer. Co-author DOI 10.1159/000492388↗
  25. Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic ductal adenocarcinoma (NUPAT 05 … Co-author DOI 10.18999/nagjms.81.2.233↗
  26. Natural history of pancreatic cystic lesions: A multicenter prospective observational study for evaluating the risk of pancreatic cancer. Co-author DOI 10.1111/jgh.13967↗
  27. A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer. Co-author DOI 10.1186/s12885-018-4453-z↗

Closest collaborators

The 25 strongest of 49 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hiroki Kawashima · 25 shared papers, 2018–2026 · strength 4.39
  2. Tadashi Iida · 16 shared papers, 2020–2026 · strength 2.87
  3. Yasuyuki Mizutani · 12 shared papers, 2022–2026 · strength 2.40
  4. Eizaburo Ohno · 19 shared papers, 2018–2024 · strength 2.33
  5. Kentaro Yamao · 8 shared papers, 2023–2026 · strength 2.08
  6. Yoshihisa Takada · 5 shared papers, 2025–2026 · strength 1.36
  7. Yoshiki Hirooka · 11 shared papers, 2018–2023 · strength 1.21
  8. Osamu Maeda · 6 shared papers, 2019–2026 · strength 1.16
  9. Mitsuhiro Fujishiro · 9 shared papers, 2020–2022 · strength 1.10
  10. Junpei Yamaguchi · 4 shared papers, 2019–2026 · strength 0.69
  11. Yukihiro Yokoyama · 4 shared papers, 2019–2026 · strength 0.69
  12. Tomoki Ebata · 3 shared papers, 2022–2026 · strength 0.62
  13. Yuichi Kano · 2 shared papers, 2026 · strength 0.59
  14. Mamoru Takenaka · 2 shared papers, 2025–2026 · strength 0.57
  15. Masatoshi Kudo · 2 shared papers, 2025–2026 · strength 0.57
  16. Kunio Kataoka · 4 shared papers, 2020–2024 · strength 0.55
  17. Suguru Yamada · 3 shared papers, 2019–2026 · strength 0.50
  18. Masakatsu Yoshikawa · 4 shared papers, 2020–2022 · strength 0.47
  19. Yasuhiro Kodera · 4 shared papers, 2018–2024 · strength 0.47
  20. Atsushi Enomoto · 3 shared papers, 2022 · strength 0.38
  21. Yuichi Ando · 1 shared paper, 2026 · strength 0.33
  22. Kazuyuki Mizuno · 1 shared paper, 2026 · strength 0.33
  23. Kenta Yamada · 3 shared papers, 2020–2021 · strength 0.31
  24. Senju Hashimoto · 3 shared papers, 2018–2023 · strength 0.30
  25. Kazunori Takeuchi · 1 shared paper, 2026 · strength 0.25

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.